Maciej L Goniewicz1,2, Michal Gawron2, Danielle M Smith1, Margaret Peng3, Peyton Jacob3, Neal L Benowitz3. 1. Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY. 2. Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland. 3. Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA.
Abstract
INTRODUCTION: Electronic cigarettes (e-cigarettes) are purported to deliver nicotine aerosol without any toxic combustion products present in tobacco smoke. In this longitudinal within-subjects observational study, we evaluated the effects of e-cigarettes on nicotine delivery and exposure to selected carcinogens and toxicants. METHODS: We measured seven nicotine metabolites and 17 tobacco smoke exposure biomarkers in the urine samples of 20 smokers collected before and after switching to pen-style M201 e-cigarettes for 2 weeks. Biomarkers were metabolites of 13 major carcinogens and toxicants in cigarette smoke: one tobacco-specific nitrosamine (NNK), eight volatile organic compounds (1,3-butadiene, crotonaldehyde, acrolein, benzene, acrylamide, acrylonitrile, ethylene oxide, and propylene oxide), and four polycyclic aromatic hydrocarbons (naphthalene, fluorene, phenanthrene, and pyrene). Changes in urine biomarkers concentration were tested using repeated measures analysis of variance. RESULTS: In total, 45% of participants reported complete abstinence from cigarette smoking at 2 weeks, while 55% reported continued smoking. Levels of total nicotine and some polycyclic aromatic hydrocarbon metabolites did not change after switching from tobacco to e-cigarettes. All other biomarkers significantly decreased after 1 week of using e-cigarettes (p < .05). After 1 week, the greatest percentage reductions in biomarkers levels were observed for metabolites of 1,3-butadiene, benzene, and acrylonitrile. Total NNAL, a metabolite of NNK, declined by 57% and 64% after 1 and 2 weeks, respectively, while 3-hydroxyfluorene levels declined by 46% at week 1, and 34% at week 2. CONCLUSIONS: After switching from tobacco to e-cigarettes, nicotine exposure remains unchanged, while exposure to selected carcinogens and toxicants is substantially reduced. IMPLICATIONS: To our knowledge, this is the first study that demonstrates that substituting tobacco cigarettes with an e-cigarette may reduce user exposure to numerous toxicants and carcinogens otherwise present in tobacco cigarettes. Data on reduced exposure to harmful constituents that are present in tobacco cigarettes and e-cigarettes can aid in evaluating e-cigarettes as a potential harm reduction device.
INTRODUCTION: Electronic cigarettes (e-cigarettes) are purported to deliver nicotine aerosol without any toxic combustion products present in tobacco smoke. In this longitudinal within-subjects observational study, we evaluated the effects of e-cigarettes on nicotine delivery and exposure to selected carcinogens and toxicants. METHODS: We measured seven nicotine metabolites and 17 tobacco smoke exposure biomarkers in the urine samples of 20 smokers collected before and after switching to pen-style M201 e-cigarettes for 2 weeks. Biomarkers were metabolites of 13 major carcinogens and toxicants in cigarette smoke: one tobacco-specific nitrosamine (NNK), eight volatile organic compounds (1,3-butadiene, crotonaldehyde, acrolein, benzene, acrylamide, acrylonitrile, ethylene oxide, and propylene oxide), and four polycyclic aromatic hydrocarbons (naphthalene, fluorene, phenanthrene, and pyrene). Changes in urine biomarkers concentration were tested using repeated measures analysis of variance. RESULTS: In total, 45% of participants reported complete abstinence from cigarette smoking at 2 weeks, while 55% reported continued smoking. Levels of total nicotine and some polycyclic aromatic hydrocarbon metabolites did not change after switching from tobacco to e-cigarettes. All other biomarkers significantly decreased after 1 week of using e-cigarettes (p < .05). After 1 week, the greatest percentage reductions in biomarkers levels were observed for metabolites of 1,3-butadiene, benzene, and acrylonitrile. Total NNAL, a metabolite of NNK, declined by 57% and 64% after 1 and 2 weeks, respectively, while 3-hydroxyfluorene levels declined by 46% at week 1, and 34% at week 2. CONCLUSIONS: After switching from tobacco to e-cigarettes, nicotine exposure remains unchanged, while exposure to selected carcinogens and toxicants is substantially reduced. IMPLICATIONS: To our knowledge, this is the first study that demonstrates that substituting tobacco cigarettes with an e-cigarette may reduce user exposure to numerous toxicants and carcinogens otherwise present in tobacco cigarettes. Data on reduced exposure to harmful constituents that are present in tobacco cigarettes and e-cigarettes can aid in evaluating e-cigarettes as a potential harm reduction device.
Authors: Stephen S Hecht; Steven G Carmella; Delshanee Kotandeniya; Makenzie E Pillsbury; Menglan Chen; Benjamin W S Ransom; Rachel Isaksson Vogel; Elizabeth Thompson; Sharon E Murphy; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2014-10-21 Impact factor: 4.244
Authors: L M Anderson; S S Hecht; D E Dixon; L F Dove; R M Kovatch; S Amin; D Hoffmann; J M Rice Journal: Cancer Res Date: 1989-07-15 Impact factor: 12.701
Authors: Maciej L Goniewicz; Christopher M Havel; Margaret Wilson Peng; Peyton Jacob; Delia Dempsey; Lisa Yu; Wioleta Zielinska-Danch; Bartosz Koszowski; Jan Czogala; Andrzej Sobczak; Neal L Benowitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254
Authors: Peyton Jacob; Christopher Havel; Do-Hoon Lee; Lisa Yu; Mark D Eisner; Neal L Benowitz Journal: Anal Chem Date: 2008-10-08 Impact factor: 6.986
Authors: Maciej Lukasz Goniewicz; Jakub Knysak; Michal Gawron; Leon Kosmider; Andrzej Sobczak; Jolanta Kurek; Adam Prokopowicz; Magdalena Jablonska-Czapla; Czeslawa Rosik-Dulewska; Christopher Havel; Peyton Jacob; Neal Benowitz Journal: Tob Control Date: 2013-03-06 Impact factor: 7.552
Authors: Peyton Jacob; Ahmad H Abu Raddaha; Delia Dempsey; Christopher Havel; Margaret Peng; Lisa Yu; Neal L Benowitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-05 Impact factor: 4.254
Authors: Hayden McRobbie; Anna Phillips; Maciej L Goniewicz; Katie Myers Smith; Oliver Knight-West; Dunja Przulj; Peter Hajek Journal: Cancer Prev Res (Phila) Date: 2015-09
Authors: Cassandra A Stanton; Eva Sharma; Kathryn C Edwards; Michael J Halenar; Kristie A Taylor; Karin A Kasza; Hannah Day; Gabriella Anic; Lisa D Gardner; Hoda T Hammad; Maansi Bansal-Travers; Jean Limpert; Nicolette Borek; Heather L Kimmel; Wilson M Compton; Andrew Hyland Journal: Tob Control Date: 2020-05 Impact factor: 7.552
Authors: Alexsandra Ratajczak; Wojciech Feleszko; Danielle M Smith; Maciej Goniewicz Journal: Expert Rev Respir Med Date: 2018-06-08 Impact factor: 3.772
Authors: Gideon St Helen; Evangelia Liakoni; Natalie Nardone; Newton Addo; Peyton Jacob; Neal L Benowitz Journal: Cancer Prev Res (Phila) Date: 2019-09-25
Authors: Gideon St Helen; Delia A Dempsey; Christopher M Havel; Peyton Jacob; Neal L Benowitz Journal: Drug Alcohol Depend Date: 2017-06-30 Impact factor: 4.492
Authors: Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-05-18 Impact factor: 5.464
Authors: Natalie Voos; Danielle Smith; Lisa Kaiser; Martin C Mahoney; Clara M Bradizza; Lynn T Kozlowski; Neal L Benowitz; Richard J O'Connor; Maciej L Goniewicz Journal: Psychopharmacology (Berl) Date: 2019-11-26 Impact factor: 4.530
Authors: David B Abrams; Allison M Glasser; Andrea C Villanti; Jennifer L Pearson; Shyanika Rose; Raymond S Niaura Journal: Prev Med Date: 2018-06-23 Impact factor: 4.018